The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major U.S. airportsBOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention’s (CDC’s) Traveler-based Genomic Surveillance program to include a pilot study monitoring influenza viruses in addition to SARS-CoV
Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurityBOSTON and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expec
Ginkgo is teaming up with Synlogic to launch a new gout drug, moving shares of both stocks higher.